Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Incyte CorporationNASDAQ: INCY

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 103.7% from a year ago

Cash & equivalents stood at $3.98B at the end of Q2 FY2026, up 103.7% from a year earlier and up 15.1% from the prior quarter. Over 3 fiscal years it compounded at +1.6% a year.

Context

  • Cash & equivalents amounted to 50.6% of total assets at the end of Q2 FY2026, up 17.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +103.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.98B+15.1% QoQ
Last fiscal yearDec 2025
$3.1B+83.5% YoY
Year agoJun 2025
$1.95B+103.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103.7%——
1 year+83.5%——
3-year CAGR+1.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
3.1B USD
Year-over-year change
+83.5%
4-year CAGR
+10.8%

Cash & Equivalents vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's Jun 2026 cash & equivalents of $3.98B is the highest of the 11 companies compared; the peer median is $371.07M.
  • Its year-over-year change of +103.7% is the 4th highest of 11, against a peer median of +53.0%.
  • Cash & equivalents amounts to 50.6% of total assets for INCY, versus a peer median of 23.0%.
INCY Competitors Peer median
Cash & Equivalents for INCY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INCYIncyte CorporationJun 2026$3.98B +103.7%+1.6%50.6%
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$2.46B +23.0%+0.1%5.9%
GMABGenmab A/SJun 2026$1.5B +16.0%-44.3%12.0%
LGNDLigand Pharmaceuticals IncorporatedJun 2026$1.01B +1387.7%+57.2%46.1%
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
LEGNLegend Biotech CorporationSep 2026$460.7M +65.2%+4.7%27.4%
EXELExelixis, Inc.Jul 2026$281.45M +71.2%-1.3%11.3%
VSTMVerastem, Inc.Mar 2026$165.55M +40.8%+39.9%72.7%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$134.71M +203.3%+61.3%95.5%
CGEMCullinan Therapeutics, Inc.Mar 2026$75.08M -2.1%-17.3%18.6%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M +24.5%-34.7%17.8%
Peer median (excluding INCY) $371.07M+53.0%+2.4%23.0%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.06B2.95B3.21B1.69B3.1B
Short-term Investments290.75M287.54M442.67M470.26M482.79M
Net Receivables616.3M644.88M743.56M853.15M1.02B
Inventory27.9M42M62.97M58.87M101.06M
Other Current Assets126.28M167.01M182.83M168.91M317.83M
Total Current Assets3.12B4.09B4.65B3.24B5.02B
Property, Plant & Equipment (Net)751.47M765.61M777.05M794.21M758.41M
Goodwill155.59M155.59M155.59M155.59M133M
Intangible Assets150.76M129.22M123.55M113.8M117.13M
Long-term Investments221.27M133.68M187.72M18.81M47.99M
Tax Assets467.54M457.94M631.89M762.07M515.29M
Other Non-current Assets68.06M106.1M260.92M360.8M(47.99M)
Total Non-current Assets1.81B1.75B2.14B2.21B1.52B
Total Assets4.93B5.84B6.78B5.44B6.96B
Account Payables172.11M277.55M109.6M197.47M209.94M
Short-term Debt000010.21M
Tax Payables07.11M42.3M23.78M0
Deferred Revenue00000
Other Current Liabilities328.26M435.86M545.01M724.83M1.07B
Total Current Liabilities854.31M1.16B1.24B1.64B1.52B
Long-term Debt000014.51M
Deferred Tax Liabilities000012.88M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities277.41M283.71M322.73M321.31M216.11M
Total Non-current Liabilities309.04M313.79M351.89M354.85M288.2M
Total Liabilities1.16B1.47B1.59B2B1.8B
Common Stock221K223K224K193K198K
Retained Earnings(777.87M)(437.21M)160.39M(1.07B)213.77M
Accumulated OCI(19.45M)15.07M13.11M(13.12M)25.46M
Other Stockholders Equity00000
Minority Interest00000
Total Equity3.77B4.37B5.19B3.45B5.17B
Total Debt44.82M41.46M38.29M43.54M69.43M
Net Debt(2.01B)(2.91B)(3.18B)(1.64B)(3.03B)

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.